Caitlin Mason1, Jean De Dieu Tapsoba, Catherine Duggan, Ikuyo Imayama, Ching-Yun Wang, Larissa A Korde, Frank Stanczyk, Anne McTiernan. 1. 1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 2Department of Biostatistics, University of Washington, Seattle, WA 3Seattle Cancer Care Alliance, Seattle, WA 4Department of Medicine, University of Washington, Seattle, WA 5University of Southern California, Keck School of Medicine, Los Angeles, CA 6Department of Epidemiology, University of Washington, Seattle, WA.
Abstract
OBJECTIVE: The aim of the study was to compare the effects of vitamin D3 supplementation versus placebo on serum sex hormones in postmenopausal women completing a 12-month diet + exercise weight loss program. METHODS:Two hundred eighteen overweight or obese women (50-75 y) withserum 25-hydroxyvitamin D at least 10 to less than 32 ng/mL ("insufficient") were randomized to either weight loss + 2,000 IU/day oral vitamin D3, or to weight loss + daily placebo. Serum sex hormone-binding globulin, estrone, total, free, and bioavailable estradiol, and testosterone were measured by radioimmunoassay before randomization and at 12 months. Mean changes were compared between groups (intent-to-treat) using generalized estimating equations. RESULTS: The 12-month changes in sex hormone-binding globulin, estrone, total, free, and bioavailable estradiol, and testosterone did not differ between groups (all P > 0.05). However, a greater increase in serum 25-hydroxyvitamin D was associated with a greater increase in sex hormone-binding globulin (Ptrend = 0.01), and larger decreases in free and bioavailable estradiol (Ptrend = 0.04, Ptrend = 0.03, respectively). In post-hoc analyses, we compared women randomized to vitamin D whose serum 25-hydroxyvitamin D remained insufficient (n = 38), to women who became replete (25-hydroxyvitamin D≥32 ng/mL; n = 53). Replete women showed greater reductions in bioavailable estradiol (-1.8 vs -0.7 pg/mL), free testosterone (-0.8 vs -0.3 pg/mL), and bioavailable testosterone (-1.8 vs -0.6 ng/dL), and a greater increase in sex hormone-binding globulin (10.6 vs 4.7 nmol/L) (all P < 0.05), even after adjusting for differences in total 12-month weight loss. CONCLUSIONS: Overall, 12-month changes in sex hormone did not differ between groups. However, vitamin D repletion was associated with greater reductions in sex hormones during weight loss, with a possible dose-dependent effect. Future studies should test higher doses and target circulating 25-hydroxyvitamin D levels when measuring such effects.
RCT Entities:
OBJECTIVE: The aim of the study was to compare the effects of vitamin D3 supplementation versus placebo on serum sex hormones in postmenopausal women completing a 12-month diet + exercise weight loss program. METHODS: Two hundred eighteen overweight or obesewomen (50-75 y) with serum 25-hydroxyvitamin D at least 10 to less than 32 ng/mL ("insufficient") were randomized to either weight loss + 2,000 IU/day oral vitamin D3, or to weight loss + daily placebo. Serum sex hormone-binding globulin, estrone, total, free, and bioavailable estradiol, and testosterone were measured by radioimmunoassay before randomization and at 12 months. Mean changes were compared between groups (intent-to-treat) using generalized estimating equations. RESULTS: The 12-month changes in sex hormone-binding globulin, estrone, total, free, and bioavailable estradiol, and testosterone did not differ between groups (all P > 0.05). However, a greater increase in serum 25-hydroxyvitamin D was associated with a greater increase in sex hormone-binding globulin (Ptrend = 0.01), and larger decreases in free and bioavailable estradiol (Ptrend = 0.04, Ptrend = 0.03, respectively). In post-hoc analyses, we compared women randomized to vitamin D whose serum 25-hydroxyvitamin D remained insufficient (n = 38), to women who became replete (25-hydroxyvitamin D ≥32 ng/mL; n = 53). Replete women showed greater reductions in bioavailable estradiol (-1.8 vs -0.7 pg/mL), free testosterone (-0.8 vs -0.3 pg/mL), and bioavailable testosterone (-1.8 vs -0.6 ng/dL), and a greater increase in sex hormone-binding globulin (10.6 vs 4.7 nmol/L) (all P < 0.05), even after adjusting for differences in total 12-month weight loss. CONCLUSIONS: Overall, 12-month changes in sex hormone did not differ between groups. However, vitamin D repletion was associated with greater reductions in sex hormones during weight loss, with a possible dose-dependent effect. Future studies should test higher doses and target circulating 25-hydroxyvitamin D levels when measuring such effects.
Authors: Karen E Foster-Schubert; Catherine M Alfano; Catherine R Duggan; Liren Xiao; Kristin L Campbell; Angela Kong; Carolyn E Bain; Ching-Yun Wang; George L Blackburn; Anne McTiernan Journal: Obesity (Silver Spring) Date: 2011-04-14 Impact factor: 5.002
Authors: K Brock; W-Y Huang; D R Fraser; L Ke; M Tseng; R Stolzenberg-Solomon; U Peters; J Ahn; M Purdue; R S Mason; C McCarty; R G Ziegler; B Graubard Journal: J Steroid Biochem Mol Biol Date: 2010-04-22 Impact factor: 4.292
Authors: Kristin L Campbell; Karen E Foster-Schubert; Catherine M Alfano; Chia-Chi Wang; Ching-Yun Wang; Catherine R Duggan; Caitlin Mason; Ikuyo Imayama; Angela Kong; Liren Xiao; Carolyn E Bain; George L Blackburn; Frank Z Stanczyk; Anne McTiernan Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Helen L Henry; Roger Bouillon; Anthony W Norman; J Christopher Gallagher; Paul Lips; Robert P Heaney; Reinhold Vieth; John M Pettifor; Bess Dawson-Hughes; Christel J Lamberg-Allardt; Peter R Ebeling Journal: J Steroid Biochem Mol Biol Date: 2010-05-24 Impact factor: 4.292
Authors: Christy G Woolcott; Yurii B Shvetsov; Frank Z Stanczyk; Lynne R Wilkens; Kami K White; Christian Caberto; Brian E Henderson; Loïc Le Marchand; Laurence N Kolonel; Marc T Goodman Journal: Endocr Relat Cancer Date: 2010-02-18 Impact factor: 5.678
Authors: T J Key; P N Appleby; G K Reeves; A W Roddam; K J Helzlsouer; A J Alberg; D E Rollison; J F Dorgan; L A Brinton; K Overvad; R Kaaks; A Trichopoulou; F Clavel-Chapelon; S Panico; E J Duell; P H M Peeters; S Rinaldi; I S Fentiman; M Dowsett; J Manjer; P Lenner; G Hallmans; L Baglietto; D R English; G G Giles; J L Hopper; G Severi; H A Morris; S E Hankinson; S S Tworoger; K Koenig; A Zeleniuch-Jacquotte; A A Arslan; P Toniolo; R E Shore; V Krogh; A Micheli; F Berrino; E Barrett-Connor; G A Laughlin; M Kabuto; S Akiba; R G Stevens; K Neriishi; C E Land; J A Cauley; Li Yung Lui; Steven R Cummings; M J Gunter; T E Rohan; H D Strickler Journal: Br J Cancer Date: 2011-07-19 Impact factor: 7.640
Authors: Daniel L Kuhr; Lindsey A Sjaarda; Zeina Alkhalaf; Ukpebo R Omosigho; Matthew T Connell; Robert M Silver; Keewan Kim; Neil J Perkins; Tiffany L Holland; Torie C Plowden; Enrique F Schisterman; Sunni L Mumford Journal: Am J Obstet Gynecol Date: 2018-03-13 Impact factor: 8.661
Authors: S Jafari-Sfidvajani; R Ahangari; M Hozoori; H Mozaffari-Khosravi; H Fallahzadeh; A Nadjarzadeh Journal: J Endocrinol Invest Date: 2017-11-06 Impact factor: 4.256
Authors: Ryan Janjuha; Diane Bunn; Richard Hayhoe; Lee Hooper; Asmaa Abdelhamid; Shaan Mahmood; Joseph Hayden-Case; Will Appleyard; Sophie Morris; Ailsa Welch Journal: Nutrients Date: 2020-05-18 Impact factor: 5.717